ArticleDiabetologia2011
The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis.
Article in Diabetologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Optimal prandial timing of bolus insulin in diabetes management: a review.Diabetic medicine : a journal of the British Diabetic Association · 2018Pooled it
- Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics.Diabetes care · 2013Trial
- Review
- Insulin level regulators may affect cognitive ability caused by motion sickness: an experimental study.Metabolic brain disease · 2025Article
- A Comprehensive Review of the Effects of Diabetes Mellitus on the Gastrointestinal System.Cureus · 2025Review
- Diet consistency modification improves postprandial glycemic and gastroparesis symptoms.Journal of diabetes and metabolic disorders · 2022Article
- [Diabetic gastroenteropathy: modern methods of diagnosis and treatment].Problemy endokrinologii · 2022Article
- Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series.Journal of diabetes science and technology · 2021Review
- Diabetic gastroenteropathy: An underdiagnosed complication.World journal of diabetes · 2021Review
- Diabetic Gastroparesis and Glycaemic Control.Current diabetes reports · 2019Review
- Diabetic Gastroparesis.Endocrine reviews · 2019Review
- Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report.Diabetes care · 2019Review
- Diabetic Gastroparesis: Principles and Current Trends in Management.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Review
- Article
- Diabetes and the Stomach.Current treatment options in gastroenterology · 2017Review
- Glucose variability, HbA1c and microvascular complications.Reviews in endocrine & metabolic disorders · 2016Review
- Severe gastrointestinal autonomic dysfunction in a diabetic boy.Endocrine · 2015Article
- Gastric emptying and glycaemia in health and diabetes mellitus.Nature reviews. Endocrinology · 2015Review
- Gastrointestinal complications of diabetes mellitus.World journal of diabetes · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
objectiveTo describe the effectiveness of continuous subcutaneous insulin infusion (CSII) in patients with symptomatic diabetic gastroparesis and unstable glycaemic control.
methodsData from 26 patients with symptomatic diabetic gastroparesis and unstable glycaemic control using multiple-dose insulin (MDI) regimens, and subsequently managed with CSII, were analysed.
resultsFollowing initiation of CSII, the median length of inpatient bed days associated with hospital admissions related to gastroparesis and glycaemic instability was reduced from 8.5 (range 0-144) days patient( -1) year( -1) prior to CSII to 0 (range 0-15) days patient( -1) year( -1). The median HbA(1c) reduction with CSII was 1.8% (22 mmol/mol; p < 0.05). The median capillary blood glucose (CBG) with CSII was significantly lower than with MDI: 7.7 mmol/l (range 3.8-15.4 mmol/l) vs 9.8 mmol/l (range 2.3-27 mmol/l), respectively, p < 0.001. Glycaemic variability with CSII was significantly reduced compared with MDI: CBG CV 0.37 vs CV 0.53, respectively, p < 0.001. CONCLUSIONS/
interpretationCSII therapy in patients with diabetic gastroparesis results in significant improvement in glycaemic control and reductions in glycaemic variability and number of hospital inpatient bed days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.